Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 63Osteosarcoma 16Leiomyosarcoma 16Neoplasm Metastasis 10Pancreatic Neoplasms 9Breast Neoplasms 9Bone Neoplasms 8Rhabdomyosarcoma 6Ovarian Neoplasms 6Neoplasms 6Colorectal Neoplasms 6Small Cell Lung Carcinoma 5Sarcoma, Ewing 5Liposarcoma 5Head and Neck Neoplasms 5Colonic Neoplasms 5Sarcoma, Synovial 4Prostatic Neoplasms 4Melanoma 4Histiocytoma, Malignant Fibrous 4Hemangiosarcoma 4Chondrosarcoma 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Recurrence 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Gastrointestinal Stromal Tumors 3Esophageal Neoplasms 3Dermatofibrosarcoma 3

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × Gemcitabine × Sarcoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡